Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 10/20 | 0.57 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.57 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.56 |
| ▸ | NOS2 | P35228 | 3/20 | 0.52 |
| ▸ | NOS3 | P29474 | 2/20 | 0.52 |
| ▸ | NOS1 | P29475 | 2/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racemethionine SCHEMBL16062299 | 1.00 | BHMT (0.57) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Methionine SCHEMBL5584463 | 1.00 | BHMT (0.57) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Racemethionine SCHEMBL9504290 | 1.00 | — | — | |
| Racemethionine SCHEMBL5617580 | 1.00 | BHMT (0.57) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Racemethionine SCHEMBL8983115 | 1.00 | BHMT (0.57) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Racemethionine SCHEMBL23361954 | 1.00 | BHMT (0.57) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Racemethionine SCHEMBL287590 | 1.00 | BHMT (0.57) | BHMTBHMT2RNPEPNOS2NOS3 | |
| Methionine SCHEMBL4226 | 1.00 | — | — | |
| Racemethionine SCHEMBL126688 | 1.00 | — | — | |
| Racemethionine SCHEMBL31367634 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024102722-A1 | METHODS OF TREATING A TUMOR WITH AN UNMETHYLATED MGMT PROMOTER | NEOIMMUNETECH, INC. (US) | 2024-05-16 | — | — | WO | claimed |
| US-20240115675-A1 | METHOD OF TREATING A TUMOR WITH A COMBINATION OF AN IL-7 PROTEIN AND A NUCLEOTIDE VACCINE | NEOIMMUNETECH, INC. (US) | 2024-04-11 | — | — | US | claimed |
| US-20240101629-A1 | USE OF INTERLEUKIN-7 FOR THE TREATMENT OF CORONAVIRUS | NEOIMMUNETECH, INC. (US) | 2024-03-28 | — | — | US | claimed |
| US-20240018205-A1 | PHARMACEUTICAL COMPOSITION COMPRISING IMMUNOGLOBULIN FC-FUSED INTERLEUKIN-7 FUSION PROTEIN FOR PREVENTING OR TREATING HUMAN PAPILLOMAVIRUS-CAUSED DISEASES | GENEXINE, INC. (KR) | 2024-01-18 | — | — | US | claimed |
| US-20230398184-A1 | METHODS OF INDUCING STEM CELL MOBILIZATION | NEOIMMUNETECH, INC. (US) | 2023-12-14 | — | — | US | claimed |
| EP-4240408-A1 | METHOD OF TREATING A TUMOR WITH A COMBINATION OF AN IL-7 PROTEIN AND A NUCLEOTIDE VACCINE | NEOIMMUNETECH, INC. (US) | 2023-09-13 | — | — | EP | claimed |
| EP-4236989-A1 | USE OF INTERLEUKIN-7 FOR THE TREATMENT OF CORONAVIRUS | NeoImmuneTech, Inc. (US) | 2023-09-06 | — | — | EP | claimed |
| EP-4232070-A1 | METHODS OF INDUCING STEM CELL MOBILIZATION | NeoImmuneTech, Inc. (US) | 2023-08-30 | — | — | EP | claimed |
| CN-116615236-A | Methods of treating tumors using combinations of IL-7 proteins and nucleotide vaccines | 新免疫技术有限公司 | 2023-08-18 | — | — | CN | claimed |
| US-11708399-B2 | Pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein for preventing or treating human papillomavirus-caused diseases | GENEXINE, INC. (KR) | 2023-07-25 | — | — | US | claimed |
| CN-108093638-A | MODIFIED INTERLEUKIN-7 PROTEIN AND USES THEREOF | 格纳西尼有限公司 | 2018-05-29 | — | — | CN | claimed |
| EP-3307766-A1 | MODIFIED INTERLEUKIN-7 PROTEIN AND USES THEREOF | Genexine, Inc. (KR) | 2018-04-18 | — | — | EP | claimed |
| US-20170158746-A1 | MODIFIED INTERLEUKIN-7 PROTEIN AND USES THEREOF | GENEXINE, INC. (KR) | 2017-06-08 | — | — | US | claimed |
| WO-2017095191-A1 | PHARMACEUTICAL COMPOSITION COMPRISING IMMUNOGLOBULIN FC-FUSED INTERLEUKIN-7 FUSION PROTEIN FOR PREVENTING OR TREATING HUMAN PAPILLOMAVIRUS-CAUSED DISEASES | 주식회사 제넥신 | 2017-06-08 | — | — | WO | claimed |
| WO-2016200219-A1 | MODIFIED INTERLEUKIN-7 PROTEIN AND USES THEREOF | GENEXINE, INC. (KR) | 2016-12-15 | — | — | WO | claimed |
| US-20100150871-A1 | Genetically-modified strain of yeast with an increased production and output of s-adenosylmethionine (sam) | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQE (FR) | 2010-06-17 | — | — | US | claimed |
| EP-1805301-A1 | GENETICALLY-MODIFIED STRAIN OF YEAST WITH AN INCREASED PRODUCTION AND OUTPUT OF S-ADENOSYLMETHIONINE (SAM) | The Centre National de la Recherche Scientifique (FR) | 2007-07-11 | — | — | EP | claimed |
| CN-1325063-C | L-amino acid water-soluble pearl powder and its preparing method | SONG TINGSHENG (CN) | 2007-07-11 | — | — | CN | claimed |
| WO-2006045953-A1 | GENETICALLY-MODIFIED STRAIN OF YEAST WITH AN INCREASED PRODUCTION AND OUTPUT OF S-ADENOSYLMETHIONINE (SAM) | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-05-04 | — | — | WO | claimed |
| CN-1709282-A | L-amino acid water-soluble pearl powder and its preparing method | SONG TINGSHENG (CN) | 2005-12-21 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100150871-A1 | Genetically-modified strain of yeast with an increased production and output of s-adenosylmethionine (sam) | AHCY, MAT2A, MAT1A | BHMT 16/4885BHMT2 14/4885RNPEP 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.